DIABESITY aims to combine neurophysiological, neuroanatomical, and systems physiological approaches to establish the functional role of genes in regulating body composition, in order to understand how manipulation of gene activity impacts upon whole body physiology, endocrinology and phenotype. We will identify novel genes and processes linked to the pathogenesis of diabesity and thereby find potential molecular drug targets. Characterisation of those drug targets, in particular by using molecular physiological studies and integrative human biology, will be followed by target validation resulting in the identification of several novel, validated drug targets for the treatment and prevention of diabesity.
Using a combination of invertebrate and mammalian genetics, DIABESITY expects to firstly identify several genes involved in the pathogenesis of diabesity. These potential drug targets will then be characterised by molecular and physiological studies resulting in the localisation of the site of expression of the targets and an understanding of their functional roles in diabesity. Once characterised, potential targets will validated (by molecular genetics and phenotypical analyses) to identifying the targets that play the major roles in diabesity, thereby providing validated novel drug targets and pharmaceutical therapies that appropriately address diabetes and obesity.
New knowledge generated by DIABESITY, primarily novel drug targets and potential pharmaceutical therapies, will be translated into applications that directly enhance human health by bringing basic knowledge through to clinical application. To this end, both fundamental and applied research will be supported, with an emphasis on integrated, multidisciplinary, and coordinated efforts that address the present fragmentation of European research and increase the competitiveness of the European biotechnology industry. By identifying potential new drug targets for the treatment and prevention of diabesity we will provide pharmacological and biotechnological SMEs with the possibility to develop novel pharmaceutical therapies.